Hanhong
Latest round
- Series A
Last raised
- Dec 2023
Total raised
- $14M
Investors
- 2
About Hanhong
Based in Shanghai, China, and founded in 2003, Hanhong is a biomedical company that focuses on new drug research and development and the drug production industry chain. It has set up a research and development center in Shanghai, and production bases in Shandong, Jiangsu, and Gansu. The company's CEO, Shizhong Ma, graduated from the East China University of Science and Technology. The company received the National SME Innovation Fund project in 2012. As of 2023, the research and development team has 120 people. The company is committed to researching, developing, manufacturing, and exporting unnatural amino acids, nucleosides, nucleotides, etc. The products include pharmaceutical intermediates, active pharmaceutical ingredients, and so on. It also provides process development of APIs and intermediates, drug discovery CRO, and other services.
Who invested in Hanhong
2 investors across 1 round
See all investors in Hanhong
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 11, 2023
Amount
$14M
Investors
Questions about Hanhong
Who invested in Hanhong?
Hanhong has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hanhong raised?
Hanhong has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Hanhong last raise money?
Hanhong's most recent round on record is a Series A, in Dec 2023.
What does Hanhong do?
Based in Shanghai, China, and founded in 2003, Hanhong is a biomedical company that focuses on new drug research and development and the drug production industry chain.
Where is Hanhong headquartered?
Hanhong is headquartered in Shanghai, China.
Which VCs invest in companies like Hanhong?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Hanhong's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Hanhong? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.